Last reviewed · How we verify
AK001 high dose
AK001 is a bispecific antibody that simultaneously engages Siglec-8 on eosinophils and mast cells while cross-linking them to trigger cell death and reduce type 2 inflammation.
AK001 is a bispecific antibody that simultaneously engages Siglec-8 on eosinophils and mast cells while cross-linking them to trigger cell death and reduce type 2 inflammation. Used for Eosinophilic gastroenteritis, Eosinophilic colitis, Mast cell activation disorder.
At a glance
| Generic name | AK001 high dose |
|---|---|
| Sponsor | Allakos Inc. |
| Drug class | Bispecific antibody |
| Target | Siglec-8 |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Mechanism of action
AK001 binds to Siglec-8, an inhibitory receptor expressed on eosinophils and mast cells, and uses its bispecific design to induce cell death of these effector cells involved in allergic and eosinophilic diseases. By depleting eosinophils and mast cells, the drug reduces the inflammatory cascade characteristic of type 2 immune responses, potentially providing therapeutic benefit in eosinophil-driven and mast cell-driven conditions.
Approved indications
- Eosinophilic gastroenteritis
- Eosinophilic colitis
- Mast cell activation disorder
Common side effects
- Infusion-related reactions
- Headache
- Fatigue
- Nausea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |